| answer text |
<p>The National Institute for Health and Care Excellence’s guidance, Chronic kidney
disease: Assessment and management [NG203], updated in November 2021, sets out the
best practice for clinicians in the diagnosis and management of chronic kidney disease
(CKD). The guidance covers monitoring for those patients at risk as well as pharmacological
management and referral, where appropriate, and is available at the following link:</p><p><a
href="https://www.nice.org.uk/guidance/ng203" target="_blank">https://www.nice.org.uk/guidance/ng203</a></p><p>In
addition to evidence-based guidance to support clinicians in diagnosing problems of
the kidney, we are also working to detect people at risk of kidney disease through
the NHS Health Check Programme. The programme, which is available for everyone between
the ages of 40 and 74 years old who are not already on a chronic disease register,
assesses people’s health and risk of developing certain health problems. Using this
information, patients are supported in making behavioural changes and accessing treatment
which helps to prevent and detect kidney disease earlier.</p><p>We are investing in
new delivery models for the NHS Health Check, including nearly £17 million for the
development and roll-out of an innovative new national and digital NHS Health Check,
which will be rolled out this spring, and will give people a choice about where and
when to have a check.</p><p>The UK National Screening Committee (UK NSC) reviewed
CKD and glomerulonephritis in 2011 and concluded that a population-wide screening
programme would not be recommended, and has not looked at the evidence for a targeted
programme. The UK NSC can be alerted to any new peer-reviewed evidence published which
may suggest the case for a new screening programme. Proposals to change or review
a topic early can be submitted via the UK NSC’s annual call, which will open in July
2024.</p>
|
|
